Zolpidem and driving impairment - Identifying persons at risk

New England Journal of Medicine

Volumn 369, Issue 8, 2013, Pages 689-691

  Farkas, Ronald H ^a   Unger, Ellis F ^a   Temple, Robert ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERMEZZO; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM TARTRATE;

ALCOHOL BLOOD LEVEL; BEDTIME DOSAGE; DOSE RESPONSE; DRIVING ABILITY; DRUG BLOOD LEVEL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; INSOMNIA; LOW DRUG DOSE; PATIENT ATTITUDE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SEX DIFFERENCE; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE; TRAFFIC ACCIDENT;

EID: 84882777037     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1307972     Document Type: Article

References (3)

1. Colten HR, Altevogt BM, eds. Sleep disorders and sleep deprivation: an unmet public health problem. Washington, DC: National Academies Press, 2006.
2. FDA drug safety communication: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) (http://www.fda.gov/Drugs/DrugSafety/ucm334033.htm).
3. FDA drug safety communication: FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR (http://www.fda.gov/Drugs/DrugSafety/ucm352085.htm).